Mometasone Furoate
Ryaltris nasal spray now available in US for patients aged 12 years and older
Olopatadine hydrochloride and mometasone furoate nasal spray is now available in the United States for the treatment of symptoms associated with seasonal allergic rhinitis in patients aged 12 years and older, according to a press release.
FDA approves Nasonex for over-the-counter use
Perrigo announced that the FDA has approved mometasone furoate monohydrate, an intranasal corticosteroid nasal spray designed to treat and prevent hay fever and allergy symptoms, for over-the-counter use.
FDA approves Ryaltris nasal spray for seasonal allergic rhinitis
The FDA approved olopatadine hydrochloride and mometasone furoate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis in adults and children aged 12 years and older, according to a press release.
Inhaler formulary changes may worsen asthma control in children
NEW ORLEANS — Switching inhaler types due to insurance formulary changes may lead to reduced lung function in children with asthma, according to data presented at the CHEST Annual Meeting.